(Q38798654)

English

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus

scientific article published on 5 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

6 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Maria Alba

1

1 reference

Europe PubMed Central

6 September 2017

John Xie

2

1 reference

Europe PubMed Central

6 September 2017

Albert Fung

3

1 reference

Europe PubMed Central

6 September 2017

Mehul Desai

4

1 reference

Europe PubMed Central

6 September 2017

language of work or name

0 references

publication date

5 April 2016

1 reference

Europe PubMed Central

6 September 2017

Current Medical Research and Opinion

1 reference

Europe PubMed Central

6 September 2017

32

1 reference

Europe PubMed Central

6 September 2017

8

1 reference

Europe PubMed Central

6 September 2017

1375-1385

1 reference

Europe PubMed Central

6 September 2017

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Biology of human sodium glucose transporters

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

The role of fat and lean mass in bone loss in older men: findings from the CHAMP study

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Effect of protein intake on bone mineralization during weight loss: a 6-month trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Bone loss accompanying voluntary weight loss in obese humans

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Role of sodium-glucose transporters in glucose uptake of the intestine and kidney

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

SGLT2 Inhibitors May Predispose to Ketoacidosis

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Influence of vitamin D status on vertebral fractures, bone mineral density, and bone turnover markers in normocalcemic postmenopausal women with high parathyroid hormone levels.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Possible adverse effects of SGLT2 inhibitors on bone

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Fibroblast growth factor-23: what we know, what we don't know, and what we need to know

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Older women with diabetes have a higher risk of falls: a prospective study

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2016.1174841

21 January 2018

Identifiers

10.1080/03007995.2016.1174841

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38798654&oldid=1787734403"